Genetic spectrum and clinical features of PMP22 point mutations in Japanese Charcot-Marie-Tooth disease
Chikashi Yano1, Masahiro Ando1, Yujiro Higuchi2
1Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, Japan.
Background:
PMP22 duplications cause Charcot-Marie-Tooth disease (CMT), whereas PMP22 deletion results in hereditary neuropathy with liability to pressure palsies (HNPP). Although PMP22 point mutations can cause a spectrum of neuropathies, including hereditary motor and sensory neuropathy (HMSN) I, congenital hypomyelinating neuropathy, HMSN III, and HNPP, they are rare, and their features in Japanese patients have not been well characterized. Therefore, we compared the genetic, clinical, and electrophysiological characteristics of patients with PMP22 point mutations.
Methods:
This multicenter study enrolled 3352 Japanese patients clinically suspected of having inherited peripheral neuropathies/CMT who underwent fluorescence in situ hybridization, multiplex ligation-dependent probe amplification, gene panel sequencing, or whole-exome analysis between 1995 and 2024. Clinical and electrophysiological data were obtained from patients' medical records.
Results:
The study enrolled 30 patients with PMP22 point mutations and 57 patients with PMP22 duplications. Among the point mutation cases, 24 distinct variants were detected, including four novel variants (p.T23K, p.R95Sfs*16, p.M111R, and p.P144R). Two splice-site variants (c.78 + 3G > T and c.79-2A > G) were associated with HNPP, whereas the others were associated with polyneuropathy. Compared with patients with PMP22 duplications, those with point mutations experienced earlier disease onset (0 vs. 35.0 years), were less likely to have a family history (14.3% vs. 61.7%), and were less frequently ambulatory (12/28 vs. 50/54). Upper limb compound muscle action potentials were more frequently undetectable in patients with point mutations (18/25 vs. 1/50).
Conclusions:
PMP22 point mutations-associated polyneuropathies were characterized by earlier disease onset and more severe effects than duplications, highlighting the broad clinical spectrum of PMP22-related neuropathies.
Insights
PMP22 point mutations cause earlier onset and more severe polyneuropathies than duplications in Japanese patients. This highlights the diverse clinical spectrum of PMP22-related inherited neuropathies.
Area of Science:
- Genetics
- Neurology
- Molecular Biology
Background:
- PMP22 gene mutations are linked to various inherited peripheral neuropathies, including Charcot-Marie-Tooth disease (CMT) and hereditary neuropathy with liability to pressure palsies (HNPP).
- While PMP22 duplications and deletions are common causes, PMP22 point mutations are rare and their clinical spectrum in Japanese populations remains undercharacterized.
- Understanding these rare mutations is crucial for accurate diagnosis and management of inherited neuropathies.
Purpose of the Study:
- To investigate and compare the genetic, clinical, and electrophysiological features of Japanese patients with PMP22 point mutations versus PMP22 duplications.
- To characterize novel PMP22 variants and their association with specific neuropathy types.
- To elucidate the full clinical spectrum of PMP22-related neuropathies.
Main Methods:
- A multicenter study involving 3352 Japanese patients with suspected inherited peripheral neuropathies from 1995 to 2024.
- Genetic analysis including fluorescence in situ hybridization, multiplex ligation-dependent probe amplification, gene panel sequencing, and whole-exome analysis.
- Retrospective collection and analysis of clinical and electrophysiological data from patient medical records.
Main Results:
- Thirty patients with PMP22 point mutations and 57 with PMP22 duplications were identified, with 24 distinct point mutations found, including four novel variants.
- PMP22 point mutations were associated with earlier disease onset (mean age 0 vs. 35 years), less frequent family history (14.3% vs. 61.7%), and reduced ambulation compared to duplications.
- Patients with point mutations showed more frequent undetectable upper limb compound muscle action potentials (18/25 vs. 1/50).
Conclusions:
- PMP22 point mutations lead to polyneuropathies with significantly earlier onset and more severe clinical manifestations than PMP22 duplications.
- The findings underscore the broad and variable clinical spectrum associated with PMP22 gene alterations.
- This study provides critical insights into the characteristics of PMP22 point mutations in Japanese patients, aiding in diagnosis and understanding of inherited neuropathies.
More Related Videos
Related Concept Videos
Incomplete Dominance
Point and Frameshift Mutations
Animal Mitochondrial Genetics
Pleiotropy
Single Nucleotide Polymorphisms-SNPs
Principles of Pharmacogenetics: Types of Genetic Variants


